1. LAST: PREVENTION AND TREATMENT PART B

2. LAST CVS and CNS toxic side effects of LA are relatively rare Potentially catastrophic complications of local and RA. These reactions are in most cases readily treatable. We will review the risk factors, presentation, and treatment of local anesthetic toxicity.

3. Mechanism of Local Anesthetic Toxicity cont. In the plasma, all LAs are bound to proteins to varying degrees, primarily to AAG and albumin. The long-duration LAs are bound by plasma proteins to a greater extent than the less potent, shorter duration LAs. Bupivacaine is ≈95% protein-bound. Intermediate-duration LAs have a smaller protein- bound fraction (60-70%). Protein binding helps to reduce the likelihood that LAs in blood will enter brain or cardiac tissue causing either CNS or cardiac toxicity

4. Mechanism of Local Anesthetic Toxicity cont. LAs may bind a wide variety of channels and enzymes in cardiac muscle and in the CNS. Lidocaine tends to produce vasodilation and negative inotropy while rarely producing arrhythmias. In contrast, bupivacaine has a greater tendency to produce ventricular arrhythmias in addition to vasodilation and negative inotropy.

5. Routes for Entry of LA into the Systemic Circulation There are three principal routes for entry of local anesthetic into the blood: 1.Direct injection into an artery or vein 2.Absorption from a depot dose in other tissues, and 3.Transcutaneous or transmucosal absorption.

6. Routes for Entry of LA into the Systemic Circulation Intravascular Injection Intravascular injection of LA agents is possible with most RA techniques due to the proximity of vascular structures to nervous tissue. E.g, accidental injection of LA into the epidural venous plexus can occur when dosing an epidural catheter, and injection into the femoral artery or vein can occur during an attempted femoral nerve block.

7. Routes for Entry of LA into the Systemic Circulation Absorption from Tissues When LA is injected into perineural connective tissue (as in a PNB) or the epidural space, the nerve- blocking action is terminated by gradual absorption from the nerve into the systemic circulation. Injecting a given dose of LA into highly vascular tissue will lead to greater plasma drug concentrations than placing the same dose of LA into a poorly vascularized site. Epinephrine is effective in retarding the rate of absorption of LA and reducing peak plasma levels of LA.

8. Routes for Entry of LA into the Systemic Circulation Transcutaneous and Transmucosal Absorption LAs can be absorbed across cutaneous and mucosal surfaces, most commonly in the oral, nasal, and tracheo-bronchial mucosa Toxic blood concentrations are possible following transcutaneous absorption of LA creams or gels, particularly in small children.

9. Risk Factors for LA Toxicity Route of Administration The location of LA injection affects its absorption rate and peak plasma concentration. The LA dose may need to be reduced when it is placed into an area with especially rapid absorption, such as the airway or in intercostal nerve blocks, as compared to sites with relatively slow absorption, such as subcutaneous injections or sciatic nerve blocks.

10. Risk Factors for LA Toxicity Young Age Infants have reduced concentrations of plasma proteins to which LAs bind, such as AAG. This leads to greater peak levels of free (unbound) LA after single injections, such as caudal epidural blocks. Infants also have a reduced capacity to metabolize LA drugs, with lower plasma clearance rates than adults This may lead to greater plasma levels when continuous infusions of LAs are given. Due to these factors, both bolus doses and infusion rates of LAs should be reduced in infants

11. Risk Factors for LA Toxicity Total Dose of LA Administered All other factors being equal, administering larger doses of local anesthetic will lead to increased plasma concentrations. Of note, it is the product of the concentration and the volume of the local anesthetic solution that is important, not either in isolation; plasma levels of local anesthetic correlate with the total mass of drug given. For example, in most cases 20 ml of a 0.25% ropivacaine solution and 10 ml of a 0.5% ropivacaine solution will produce the same peak plasma concentration.

12. Risk Factors for LA Toxicity Presence of Epinephrine Addition of epinephrine to LA solutions will normally reduce the rate of absorption and peak plasma levels. Epinephrine 1:400,000 to 1:200,000 is as effective as more concentrated solutions, while having a reduced risk of SEs such as hypertension, tachycardia, and arrhythmias.

13. Risk Factors for LA Toxicity Renal Dysfunction Patients with uremia have a hyperdynamic circulatory state, and they have a more rapid absorption of local anesthetic, with higher peak plasma levels than in non-uremic patients. Partially offsetting this effect, uremic patients have greater levels of AAG than non-uremic patients. It is recommended that a dose reduction of 10- 20% be applied when administering LAs to patients with renal dysfunction.

14. Risk Factors for LA Toxicity Liver Dysfunction Mild hepatic dysfunction appears to have a minimal effect on LA levels. In ESLD there is a significant reduced hepatic clearance rates for LAs. It is recommended that normal doses of LA may be used for single-dose techniques in patients with liver dysfunction. Continuous infusions must be significantly reduced in patients with hepatic dysfunction due to their lower rate of clearance of these drugs. Dose reductions of 10-50% have been suggested based on the severity of the hepatic dysfunction.

15. Risk Factors for LA Toxicity Heart Failure Mild, well-controlled HF may not require any reduction in local anesthetic dosing. In patients with severe heart failure, however, clearance of local anesthetic drugs may be substantially reduced due to decreased hepatic blood flow and clearance.

16. Risk Factors for LA Toxicity Pregnancy Pregnant patients have increased sensitivity to LAs, allowing dose reductions. They also have a reduced degree of protein binding of LAs. Because of the increased sensitivity and higher risk of toxic effects, LA doses should be reduced in pregnant patients. Other factors, including the reduced spinal CSF volume in pregnancy, lead to an exaggerated spread of spinal and epidural local anesthetics.

17. Signs and Symptoms of LA Toxicity CV Signs and Symptoms In general, cardiac signs of LA intoxication include:  Transient hypertension and tachycardia (especially if epinephrine is present)  Hypotension  Bradycardia  Cardiac arrhythmias, including premature ventricular contractions, ventricular tachycardia, ventricular fibrillation, pulseless electrical activity, and cardiac arrest.

18. Signs and Symptoms of LA Toxicity CNS Signs and Symptoms After an accidental IV injection, LAs produce S&S of CNS toxicity at lower doses and earlier than S&S of CV toxicity. However, the longer-acting LAs may produce toxicity in the CNS and myocardium simultaneously, or CV toxicity without any CNS SEs. Early S&S: Perioral or tongue numbness or tingling, altered or metallic taste sensation, lightheadedness or vertigo, anxiety or panic, confusion, somnolence Late s&s: Seizure activity (generally tonicclonic), depressed LOC or coma, respiratory depression or arrest

19. Treatment of Systemic LA Toxicity Rx for systemic LA toxicity should be guided by the form of toxicity (CNS vs. CV vs. allergy) and the LA agent used. In general, milder symptoms should be treated with more conservative actions. Nevertheless, mild CNS symptoms may rapidly progress into LA cardiotoxicity with arrhythmias and cardiac arrest, and one should frequently re-evaluate whether more aggressive therapies are required.

20. Treatment of LA CNS Toxicity Mild-to-moderate S&S of LA toxicity (e.g., tinnitus, lightheadedness, tremulousness, myoclonic jerks, or confusion) without seizure activity or signs of cardiac toxicity, conservative Rx (reassurance and mild sedation and anxiolysis with benzodiazepines) Severe CNS S&S (Loss of consciousness or seizures) standard resuscitation measures should begin including ABCD. LA-induced seizures medications include benzodiazepines, barbiturates, and propofol

21. Treatment of LA CV Toxicity: Antiarrhythmics If unexplained ↓BP, ↓HR, or arrhythmias are detected, Rx for suspected LACV toxicity should begin without delay. Resuscitation may require prolonged and extensive resuscitative efforts, particularly with bupivacaine-induced toxicity, and may prove unsuccessful. Rx may begin with standard ACLS methods, but we recommend some minor changes to the standard protocols

22. Treatment of LA CV Toxicity: Antiarrhythmics We omit lidocaine from resuscitation due to its potential to produce an additive effect with the "intoxicating" LA agent. We suspect that amiodarone may be a better choice for Rx of ventricular arrhythmias, conclusive data are lacking Local anesthetic cardiac toxicity will often include depressed contractility. One should avoid administering other negative inotropes in LA CV toxicity which often include depressed contractility.

23. Treatment of LA CV-toxicity: Lipid Emulsion Infusion of a 20% lipid emulsion solution (such as Intralipid™) appears to be an effective Rx for severe LA cardiotoxicity. Boluses and short-term infusions of 20% lipid emulsion have no important side effects. The mechanism by which 20% lipid emulsion negates local anesthetic toxicity is not clear.

24. Treatment of LA Cardiotoxicity: CPB CV-toxicity associated with long-acting LA agents toxicity can be quite refractory to standard ACLS resuscitation methods. Resuscitation efforts may be prolonged, with some patients potentially not responding to std drugs and therapies. When all other methods have failed, CPB for CP support and to allow time for clearance of a sufficient quantity of the LA from target tissues to permit survival should be considered. There are case reports of successful resuscitations using CPB after all other therapies have failed.

25. References http://www.hsrsna.com/student/LA_Toxicity.P DF http://www.hsrsna.com/student/LA_Toxicity.P DF